查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466688

基因治療市場：按類型、載體類型、應用分類 - 2024-2030 年全球預測

Gene Therapy Market by Type (Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy), Vector Type (Non-viral Vectors, Viral Vectors), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年基因治療市場規模為56.7億美元，預計2024年將達70.5億美元，2030年將達到304.8億美元，複合年成長率為27.15%。

基因治療是一種將遺傳物質引入、改變或修飾到個別細胞中以治療或預防疾病的醫療程序。基因治療的主要目的是透過替換或修復缺陷基因、引入治療基因、調節基因表現來解決遺傳性疾病。該領域在從根本上治療各種遺傳性和後天性疾病方面具有巨大潛力。有幾個因素促進了基因治療市場的成長，包括慢性病盛行率的增加、基因治療接受率的提高、臨床試驗的激增以及製藥領域研發支出的增加。然而，這些療法的成本非常高，並且涉及複雜且漫長的開發過程。此外，對脫靶效應、免疫抗原性和長期安全性的擔憂可能會阻礙市場需求。同時，先進技術的發展正在開闢基因編輯和治療領域幾個以前無法進入的前沿領域。由於監管機構擴大核准基因治療產品，基因治療市場預計將進一步成長，為標靶疾病治療提供許多潛在機會。

主要市場統計
基準年[2023] 56.7億美元
預測年份 [2024] 70.5億美元
預測年份 [2030] 304.8億美元
複合年成長率（%） 27.15%

類型：癌症基因治療普及

抗原基因治療涉及將編碼特定抗原的基因引入患者的細胞中。目標是刺激免疫系統識別表達這些抗原的細胞並針對它們產生免疫反應。這種方法通常被用於癌症免疫療法，它鼓勵免疫系統瞄準並消除癌細胞。癌症基因療法旨在透過針對癌細胞的特定方面來治療或消除癌症。這種治療方法使用基因編輯技術來糾正與癌症相關的特定基因突變。細胞激素基因療法涉及將編碼特定細胞激素的基因引入患者的細胞中。這種方法旨在透過引入產生免疫刺激細胞激素因子的基因來提高免疫系統識別和消除癌細胞的能力。自殺基因療法，也稱為基因定向酶前驅藥物療法（GDEPT），涉及將編碼酶的基因引入目標細胞。基因產生的酵素活化前驅藥物（無毒物質）並選擇性地將它們轉化為目標細胞內的有毒藥物。這種方法常用於癌症治療以誘導癌細胞凋亡。抑癌基因治療的重點是恢復或增強抑癌基因的功能。抑癌基因療法旨在替代或激活這些基因來控制或抑制癌細胞的生長。

載體類型：顯著利用病毒載體來提高基因轉移到細胞的效率

在基因治療中，非病毒載體是不涉及病毒的載體或遞送系統。這些載體將治療性遺傳物質（例如 DNA 或 RNA）傳遞至目標細胞以治療或預防疾病。非病毒載體的優點是在免疫抗原性方面比病毒載體更安全、更容易生產、整合到宿主基因組的風險更低。病毒載體是源自病毒的載體或載體，經過修飾可將治療性遺傳物質傳遞至目標細胞，作為基因治療的一部分。這些載體利用病毒進入細胞和傳遞基因的天然能力，並且設計為安全有效。病毒載體是許多基因治療策略的關鍵，因為它們可以有效地將基因傳遞到細胞中。

應用：基因療法可作為治療心血管疾病的創新方法

基因療法已成為治療心血管疾病的突破性方法。它主要側重於將基因引入細胞中以替換、惰性或引入新的遺傳物質來治療或控制心血管疾病。基因治療的進展為阻止遺傳疾病的進展提供了一條有前途的治療途徑。基因療法透過解決導致遺傳疾病的潛在遺傳異常，在治療遺傳疾病方面具有巨大潛力。基因治療可以透過多種增強宿主免疫反應、開發抗病毒藥物和直接針對傳染源的策略，在對抗感染疾病方面發揮作用。基因療法透過解決神經系統疾病背後的遺傳和分子異常，有助於治療神經系統疾病。基因療法在腫瘤學領域有望治療各種類型的癌症。腫瘤學基因治療的目標是針對並糾正導致癌症發生、生長和抗治療性的遺傳因素。

區域洞察

由於基因治療研究和創新的興起以及該領域的大量投資，美洲成為一個重要的地區。基因治療市場正在快速成長，這主要是由於慢性病盛行率的改善、基因研究的資金投入、行業參與者的強大以及 FDA 的核准對基因治療趨勢產生重大影響。歐洲地區憑藉其成熟的製藥公司和先進的基因治療研究，在基因治療領域顯示出可觀的成長。歐盟（EU）大力投資醫療保健研究，包括基因治療。各國在治療性臨床試驗方面處於領先地位，特別是在癌症、心血管和遺傳疾病方面。亞太地區是基因治療領域快速新興的市場。蓬勃發展的生物技術產業和大量政府資助正在推動臨床試驗的激增，而創新基因療法研究的快速進展進一步推動了市場需求的成長。總體而言，亞太地區基因治療的成長是由大量患者數量、不斷上升的醫療成本和不斷變化的法規環境共同推動的。

FPNV定位矩陣

FPNV定位矩陣對於評估基因治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對基因治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.基因治療市場的市場規模與預測是多少？

2.在基因治療市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.基因治療市場的技術趨勢和法規結構是什麼？

4.基因治療市場主要廠商的市場佔有率是多少？

5.進入基因治療市場合適的形式和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病盛行率上升，治療中心數量迅速增加
      • 政府對基因治療的支持與道德接受
    • 抑制因素
      • 基因治療相關的高成本
    • 機會
      • 持續研究和開發罕見疾病和基因治療進展
      • 創新的支付模式和有利的監管核准
    • 任務
      • 新基因療法的潛在有害影響和道德擔憂
  • 市場區隔分析
    • 類型：癌症基因療法在癌症治療的普及
    • 載體類型：病毒載體的大量利用提高了基因遞送至細胞的效率
    • 應用：基因療法作為治療心血管疾病的創新方法的潛在應用
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章 基因治療市場：依類型

  • 抗原基因治療
  • 癌症基因治療
  • 細胞激素基因治療
  • 自殺基因治療
  • 抑癌基因治療

第7章基因治療市場：依載體類型

  • 非病毒載體
  • 病毒載體

第8章基因治療市場：依應用分類

  • 心血管疾病
  • 遺傳疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤性疾病

第9章 北美和南美基因治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區基因治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的基因治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • Charles River 推出 Lentilation 平台以加速基於 LVV 的基因治療製造
    • Laurus 在印度推出基因治療資產
    • 藍鳥生物準備推出基因療法作為鐮狀疾病的應用方法

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-437517DB6C62

[196 Pages Report] The Gene Therapy Market size was estimated at USD 5.67 billion in 2023 and expected to reach USD 7.05 billion in 2024, at a CAGR 27.15% to reach USD 30.48 billion by 2030.

Gene therapy is a medical procedure that introduces, alters, or corrects genetic material within an individual's cells to treat or prevent disease. The primary purpose of gene therapy is to address genetic disorders by replacing or repairing faulty genes, introducing therapeutic genes, or regulating the expression of genes. This field holds great promise for treating various genetic and acquired diseases at their root cause. Several factors are contributing to the growth of the gene therapy market, including an increase in the prevalence of chronic conditions, a rise in acceptance of gene therapy treatment, a surge in clinical trials, and escalated R&D expenditure in the pharmaceutical sector. However, the cost of these therapies is exceptionally high, accompanied by a complex and lengthy development process. Additionally, concerns regarding off-target effects, immunogenicity, and long-term safety may hamper its market demand. Moreover, advanced technology development has opened several previously inaccessible gene editing and therapy frontiers. The gene therapy market is anticipated to grow further due to regulatory authorities' rising approval of gene therapy products, which brought forth many potential opportunities with targeted disease treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 5.67 billion
Estimated Year [2024] USD 7.05 billion
Forecast Year [2030] USD 30.48 billion
CAGR (%) 27.15%

Type: Prevalence of cancer gene therapy for cancer treatment

Antigen gene therapy introduces genes that encode specific antigens into a patient's cells. The goal is stimulating the immune system to recognize and mount an immune response against cells expressing these antigens. This approach is often explored in cancer immunotherapy, where the immune system is encouraged to target and eliminate cancer cells. Cancer gene therapy aims to treat or eliminate cancer by targeting specific aspects of cancer cells. This therapy uses gene editing technologies to modify or correct specific genetic mutations associated with cancer. Cytokine gene therapy involves introducing genes encoding specific cytokines into the patient's cells. This approach aims to enhance the immune system's capacity to identify and eliminate cancer cells by introducing genes that produce immune-stimulating cytokines. Suicide gene therapy, also known as gene-directed enzyme prodrug therapy (GDEPT), involves introducing a gene that encodes an enzyme into target cells. The enzyme produced by the gene activates a prodrug (a non-toxic substance), converting it into a toxic drug selectively in the target cells. This approach is often used in cancer therapy to cause apoptosis in cancer cells. Tumor suppressor gene therapy focuses on restoring or enhancing the function of tumor suppressor genes. Tumor suppressor gene therapy aims to either replace or activate these genes to control or inhibit the growth of cancer cells.

Vector Type: Significant utilization of viral vector providing higher efficiency in delivering genes into cells

Non-viral vectors in gene therapy are carriers or delivery systems that do not involve viruses. These vectors transport therapeutic genetic material, such as DNA or RNA, into target cells to treat or prevent diseases. Non-viral vectors are considered safer in terms of immunogenicity than viral vectors and have some advantages in terms of ease of production and reduced risk of integration into the host genome. Viral vectors are vehicles or carriers derived from viruses modified to deliver therapeutic genetic material into target cells as part of gene therapy. These vectors are engineered to be safe and effective, taking advantage of the natural ability of viruses to enter cells and deliver their genetic payload. Viral vectors are key to many gene therapy strategies because they efficiently deliver genes into cells.

Application: Potential adoption of gene therapy as a revolutionary approach to treating cardiovascular diseases

Gene therapy has appeared as a revolutionary method to treating cardiovascular diseases. It mainly focuses on delivering genes to replace, inactivate, or introduce new genetic material to cells to cure or manage cardiovascular illness. Advancements in gene therapy offer promising treatment pathways to hinder the progression of genetic diseases. Gene therapy holds significant promise in treating genetic diseases by addressing the underlying genetic abnormalities that cause these conditions. Gene therapy can play a role in combating infectious diseases through various strategies to enhance the host's immune response, develop antiviral agents, or directly target the infectious agent. Gene therapy holds promise for treating neurological diseases by addressing the underlying genetic and molecular abnormalities associated with these disorders. Gene therapy holds promise in oncology for treating various types of cancer. The goal of gene therapy in oncology is to target and modify the genetic factors contributing to cancer development, growth, and resistance to treatment.

Regional Insights

The Americas has a significant landscape in gene therapy owing to rising research and innovation with significant investments in this domain. The gene therapy market has witnessed exponential growth, mainly due to the improved prevalence of chronic diseases, availability of funding for genetic research, a strong presence of industry players, and FDA approvals that significantly impact gene therapy trends. The European region shows considerable growth in the gene therapy sector due to advanced research in gene therapy due to its well-established pharmaceutical companies. The European Union invests heavily in healthcare research, including gene therapy. Countries lead in therapeutic clinical trials, particularly in oncology, cardiovascular, and inherited diseases. The Asia-Pacific region is a rapidly emerging market in the arena of gene therapy. The surge in clinical trials spurred by its burgeoning biotech sector and substantial government funding, fast-track innovative gene therapy research is further fueled by expanded market demand. Overall, the APAC region's growth in gene therapy is driven by a combination of large patient populations, growing healthcare expenditure, and evolving regulatory environments.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gene Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gene Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, AGC Biologics., Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Applied Genetic Technologies Corporation, Astellas Gene Therapies, Biogen Inc., Bluebird Bio, Inc., Cellectis, Inc., Editas Medicine, Inc., Human Stem Cells Institute, Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Mustang Bio, Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics, Inc., and Uniqure N.V..

Market Segmentation & Coverage

This research report categorizes the Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Antigen Gene Therapy
    • Cancer Gene Therapy
    • Cytokine Gene Therapy
    • Suicide Gene Therapy
    • Tumor Suppressor Gene Therapy
  • Vector Type
    • Non-viral Vectors
    • Viral Vectors
  • Application
    • Cardiovascular Diseases
    • Genetic Diseases
    • Infectious Diseases
    • Neurological Diseases
    • Oncological Disorders
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Gene Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gene Therapy Market?

3. What are the technology trends and regulatory frameworks in the Gene Therapy Market?

4. What is the market share of the leading vendors in the Gene Therapy Market?

5. Which modes and strategic moves are suitable for entering the Gene Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
      • 5.1.1.2. Government Support and Ethical Acceptance of Gene Therapy For Treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High Costs Associated with Gene Therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research & Development in Orphan Diseases and Advancements in Gene Therapy
      • 5.1.3.2. Innovative Payment Models and Favorable Regulatory Approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Potential Harmful Effects and Moral Concerns Regarding New Gene Therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Prevalence of cancer gene therapy for cancer treatment
    • 5.2.2. Vector Type: Significant utilization of viral vector providing higher efficiency in delivering genes into cells
    • 5.2.3. Application: Potential adoption of gene therapy as a revolutionary approach to treating cardiovascular diseases
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Gene Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Antigen Gene Therapy
  • 6.3. Cancer Gene Therapy
  • 6.4. Cytokine Gene Therapy
  • 6.5. Suicide Gene Therapy
  • 6.6. Tumor Suppressor Gene Therapy

7. Gene Therapy Market, by Vector Type

  • 7.1. Introduction
  • 7.2. Non-viral Vectors
  • 7.3. Viral Vectors

8. Gene Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Genetic Diseases
  • 8.4. Infectious Diseases
  • 8.5. Neurological Diseases
  • 8.6. Oncological Disorders

9. Americas Gene Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gene Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gene Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
    • 12.3.2. Laurus to launch Gene Therapy Assets in India
    • 12.3.3. Bluebird bio Lays Gene Therapy Launch Groundwork As Sickle Cell Application Nears

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENE THERAPY MARKET DYNAMICS
  • FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. CANADA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 62. CANADA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. MEXICO GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. MEXICO GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. UNITED STATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. UNITED STATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 76. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. AUSTRALIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. AUSTRALIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CHINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. CHINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. INDIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. INDIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. INDIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. INDIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. INDONESIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. INDONESIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. INDONESIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. INDONESIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. JAPAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 114. JAPAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. MALAYSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. MALAYSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. MALAYSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. MALAYSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. PHILIPPINES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. PHILIPPINES GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. SINGAPORE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. SINGAPORE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. SINGAPORE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. SINGAPORE GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. SOUTH KOREA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. TAIWAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. TAIWAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. TAIWAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. TAIWAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. THAILAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. THAILAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. THAILAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. THAILAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. VIETNAM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. VIETNAM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. VIETNAM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. VIETNAM GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. DENMARK GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. DENMARK GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. DENMARK GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. DENMARK GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. EGYPT GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. EGYPT GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. EGYPT GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. EGYPT GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. FINLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. FINLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. FINLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. FINLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. FRANCE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. FRANCE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. FRANCE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. FRANCE GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. GERMANY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. GERMANY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. GERMANY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. GERMANY GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. ISRAEL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. ISRAEL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. ISRAEL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. ISRAEL GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. ITALY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. ITALY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. ITALY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. ITALY GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. NETHERLANDS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. NETHERLANDS GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. NIGERIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. NIGERIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. NIGERIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. NIGERIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. NORWAY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. NORWAY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. NORWAY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. NORWAY GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. POLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. POLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. POLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. POLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. QATAR GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. QATAR GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. QATAR GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 236. QATAR GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. RUSSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. RUSSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. RUSSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. RUSSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SPAIN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SPAIN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SPAIN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. SPAIN GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SWEDEN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. SWEDEN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. SWEDEN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. SWEDEN GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. SWITZERLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. SWITZERLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. TURKEY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. TURKEY GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. TURKEY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. TURKEY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. TURKEY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. TURKEY GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 290. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 291. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 292. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023